MedTrace Logo

Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses

NCT03971578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2023-08-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to develop an Auditory Brainstem Response (ABR) based neurological screening method to detect increased risk for Autism Spectrum Disorders (ASD) and other neurological conditions in newborns.

Conditions

Interventions

OTHER

No Intervention Provided

No Intervention Provided

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Intelligent Hearing Systems

    lead INDUSTRY

Eligibility

Min Age
42 Months
Max Age
54 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971578 on ClinicalTrials.gov